Amgen scores FDA's 'breakthrough' nod for prospective leukemia therapy

Amgen ($AMGN) nabbed a breakthrough designation for its mid-stage blood cancer drug blinatumomab, which delivered promising Phase II data in adults with two specific types of acute lymphoblastic leukemia. Report